Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab

Kinga Nowicka-Matus; Giedrius Salkus; Mads Sønderkær; Inge Søkilde Pedersen; Anja Ernst; Magdalena Kubik; Zsuzsanna Takacs-Szabo; Morten Ladekarl

doi:10.1200/PO.23.00173

Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab

Kinga Nowicka-Matus^*, Giedrius Salkus, Mads Sønderkær, Inge Søkilde Pedersen, Anja Ernst, Magdalena Kubik, Zsuzsanna Takacs-Szabo, Morten Ladekarl

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

48 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	e2300173
Tidsskrift	JCO Precision Oncology
Vol/bind	7
ISSN	2473-4284
DOI	https://doi.org/10.1200/PO.23.00173
Status	Udgivet - 18 aug. 2023

Adgang til dokumentet

10.1200/PO.23.00173Licens: CC BY-NC-ND 4.0

Nowicka-Matus et al. (2023). Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and PertuzumabForlagets udgivne version, 1,25 MBLicens: CC BY-NC-ND 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Nowicka-Matus, K., Salkus, G., Sønderkær, M., Søkilde Pedersen, I., Ernst, A., Kubik, M., Takacs-Szabo, Z., & Ladekarl, M. (2023). Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab. JCO Precision Oncology, 7, Artikel e2300173. https://doi.org/10.1200/PO.23.00173

@article{906e1f7bd4684d32bd4f7da4a11b7331,

title = "Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab",

keywords = "Humans, Female, Trastuzumab/therapeutic use, Paclitaxel/therapeutic use, Breast Neoplasms, Carcinoma",

author = "Kinga Nowicka-Matus and Giedrius Salkus and Mads S{\o}nderk{\ae}r and {S{\o}kilde Pedersen}, Inge and Anja Ernst and Magdalena Kubik and Zsuzsanna Takacs-Szabo and Morten Ladekarl",

year = "2023",

month = aug,

day = "18",

doi = "10.1200/PO.23.00173",

language = "English",

volume = "7",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

Nowicka-Matus, K , Salkus, G , Sønderkær, M , Søkilde Pedersen, I , Ernst, A , Kubik, M , Takacs-Szabo, Z & Ladekarl, M 2023, 'Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab', JCO Precision Oncology, bind 7, e2300173. https://doi.org/10.1200/PO.23.00173

Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab. / Nowicka-Matus, Kinga ; Salkus, Giedrius ; Sønderkær, Mads et al.
I: JCO Precision Oncology, Bind 7, e2300173, 18.08.2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab

AU - Nowicka-Matus, Kinga

AU - Salkus, Giedrius

AU - Sønderkær, Mads

AU - Søkilde Pedersen, Inge

AU - Ernst, Anja

AU - Kubik, Magdalena

AU - Takacs-Szabo, Zsuzsanna

AU - Ladekarl, Morten

PY - 2023/8/18

Y1 - 2023/8/18

KW - Humans

KW - Female

KW - Trastuzumab/therapeutic use

KW - Paclitaxel/therapeutic use

KW - Breast Neoplasms

KW - Carcinoma

U2 - 10.1200/PO.23.00173

DO - 10.1200/PO.23.00173

M3 - Journal article

C2 - 37595182

SN - 2473-4284

VL - 7

JO - JCO Precision Oncology

JF - JCO Precision Oncology

M1 - e2300173

ER -